According to several independent studies, the Vietnam diagnostic laboratory services market is projected to increase from USD 1.12 billion (equivalent to nearly VND 30 trillion, or around 20% of the private pharmaceutical retail market) in 2025 to USD 1.83 billion by 2031, representing a projected CAGR of 8.53% per year. Growth during the forecast period is expected to be driven by:
In US, the laboratory testing market has widely adopted the “B2B referral” model, whereby hospitals, clinics, and healthcare facilities send specimens to external labs rather than conducting in-house. This represents a major source of revenue and testing volume for clinical laboratories. Over the past 15 years, companies in this sector have recorded gross margins of around 30–40% and net margins of 4-15% (typically above 8%), highlighting the efficiency of a centralized model once sufficient scale is achieved.
In the case of Long Chau and FRT’s investment opportunity, the rollout of sample collection points and partnerships with specialized laboratories (LabHouse & Gene Solutions, since Aug26) allow the chain to test demand and expand its portfolio before making deeper investments in centralized lab capabilities. At sufficient scale, this model could support expansion from B2C collection points to healthcare facilities and corporate clients. We see significant growth potential for Long Chau, supported by its customer reach through ~3,000 pharmacies and VCs. However, given that the business is still at an early stage of implementation, the laboratory testing segment is unlikely to make a significant contribution to financial results over the next 1-2 years.